Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 45, 2013, Pages 18214-18219

  Alam, S Munir ^a,b   Dennison, S Moses ^a   Aussedat, Baptiste ^c   Vohra, Yusuf ^c   Park, Peter K ^c   Fernández Tejada, Alberto ^c   Stewart, Shelley ^a   Jaeger, Frederick H ^a   Anasti, Kara ^a   Blinn, Julie H ^a   Kepler, Thomas B ^d   Bonsignori, Mattia ^a,b   Liao, Hua Xin ^a,b   Sodroski, Joseph G ^e,f,g,h   Danishefsky, Samuel J ^c,i   Haynes, Barton F ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; GLYCOPEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MANNOSE OLIGOSACCHARIDE; NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE;

ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DERIVATIZATION; DIMERIZATION; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECONDARY STRUCTURE; VIRUS ENVELOPE;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; DIMERIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCOPEPTIDES; HIV-1; PROTEIN BINDING; RECEPTORS, ANTIGEN, B-CELL; SURFACE PLASMON RESONANCE;

EID: 84887315888     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1317855110     Document Type: Article

References (42)

1. Burton DR, Poignard P, Stanfield RL, Wilson IA (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091):183-186.
2. Kwong PD, Mascola JR (2012) Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 37(3):412-425.
3. Wu X, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993):856-861.
4. Wu X, et al.; NISC Comparative Sequencing Program (2011) Focused evolution of HIV- 1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049):1593-1602.
5. Scheid JF, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333(6049):1633-1637.
6. Sattentau QJ, McMichael AJ (2010) New templates for HIV-1 antibody-based vaccine design. F1000 Biol Reports 2:60.
7. Mascola JR, Haynes BF (2013) HIV-1 neutralizing antibodies: Understanding nature's pathways. Immunol Rev 254(1):225-244.
8. Haynes BF, Kelsoe G, Harrison SC, Kepler TB (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30(5):423-433.
9. Chen W, et al. (2008) All known cross reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time. AIDS Res Hum Retroviruses 24:11-12.
10. Doores KJ, Burton DR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84(20):10510-10521.
11. Ma BJ, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7(9):e1002200.
12. Pancera M, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: Structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84(16):8098-8110.
13. Xiao X, et al. (2009) Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390(3):404-409.
14. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275-1286.
15. Montefiori DC, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206(3): 431-441.
16. Liao HX, et al. (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38(1):176-186.
17. McLellan JS, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480(7377):336-343.
18. Aussedat B, et al. (2013) Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J Am Chem Soc 135(35): 13113-13120.
19. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-289.
20. Tam JP, Wu C-R, Liu W, Zhong JW (1991) Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and application. J Am Chem Soc 113(17):6657-6662.
21. Greenfield NJ (2006) Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1(6):2876-2890.
22. Wan Q, Danishefsky SJ (2007) Free-radical-based, specific desulfurization of cysteine: A powerful advance in the synthesis of polypeptides and glycopolypeptides. Angew Chem Int Ed Engl 46(48):9248-9252.
23. Bonsignori M, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85(19):9998-10009.
24. Alam SM, et al. (2013) Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87(3):1554-1568.
25. Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2(3): 347-356.
26. Finzi A, et al. (2010) Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods 168(1-2): 155-161.
27. Julien JP, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 110(11):4351-4356.
28. Walker LM, et al.; Protocol G Principal Investigators (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470.
29. Khakshoor O, Nowick JS (2009) Use of disulfide "staples" to stabilize β-sheet quaternary structure. Org Lett 11(14):3000-3003.
30. Quinn TP, Tweedy NB, Williams RW, Richardson JS, Richardson DC (1994) Betadoublet: De novo design, synthesis, and characterization of a beta-sandwich protein. Proc Natl Acad Sci USA 91(19):8747-8751.
31. Venkatraman J, Nagana Gowda GA, Balaram P (2002) Design and construction of an open multistranded beta-sheet polypeptide stabilized by a disulfide bridge. J Am Chem Soc 124(18):4987-4994.
32. Yan Y, Erickson BW (1994) Engineering of betabellin 14D: Disulfide-induced folding of a beta-sheet protein. Protein Sci 3(7):1069-1073.
33. Mayo KH, Ilyina E, Park H (1996) A recipe for designing water-soluble, betasheet- forming peptides. Protein Sci 5(7):1301-1315.
34. Nesloney CL, Kelly JW (1996) Progress towards understanding β-sheet structure. Bioorg Med Chem 4(6):739-766.
35. Dyson HJ, Wright PE (1991) Defining solution conformations of small linear peptides. Annu Rev Biophys Biophys Chem 20:519-538.
36. Santiveri CM, León E, Rico M, Jiménez MA (2008) Context-dependence of the contribution of disulfide bonds to beta-hairpin stability. Chemistry 14(2):488-499.
37. Amin MN, et al. (2013) Synthetic glycopeptides reveal the glycan specificity of HIVneutralizing antibodies. Nat Chem Biol 9(8):521-526.
38. Steers NJ, et al. (2012) HIV-1 envelope resistance to proteasomal cleavage: Implications for vaccine induced immune responses. PLoS One 7(8):e42579.
39. de Souza MS, et al.; Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Collaborators (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188(10):5166-5176.
40. Munshaw S, Kepler TB (2010) SoDA2: A Hidden Markov Model approach for identification of immunoglobulin rearrangements. Bioinformatics 26(7):867-872.
41. Alam SM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178(7):4424-4435.
42. Alam SM, et al. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: Antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82(1):115-125.